Loading...
•
Mar 31, 2021
Zai Lab Q1 2021 Earnings Report
Zai Lab's first quarter 2021 financial results were reported, showing solid revenue growth and strategic collaborations.
Key Takeaways
Zai Lab reported a net product revenue increase to $20.1 million, driven by ZEJULA and Optune, along with strategic collaborations to strengthen their oncology and autoimmune franchises. The company also significantly bolstered its capital position with a global public offering, but reported a net loss of $232.9 million due to increased R&D expenses from new business development activities.
Entered strategic collaborations to strengthen gastric and lung cancer disease strongholds.
Bolstered autoimmune franchise with an exclusive agreement for efgartigimod.
Gained regulatory approval for QINLOCK, marking the third innovative oncology product approval in 15 months in China.
Completed a global public offering with gross proceeds of nearly $860 million.
Zai Lab
Zai Lab
Zai Lab Revenue by Segment
Revenue by Segment
ZEJULA Revenue
CapyFin.com Forward Guidance
Zai Lab anticipates several milestones throughout 2021, including potential approval of Nuzyra, regulatory filings for margetuximab, Tumor Treating Fields, and ZEJULA in China, and numerous data readouts from ongoing clinical trials.
Positive Outlook
- Expect approval of Nuzyra for CABP and ABSSSI by the NMPA.
- Plan to file margetuximab for Her2-positive breast cancer in China.
- Plan to file Tumor Treating Fields for mesothelioma in China.
- Plan to file ZEJULA for late-line ovarian cancer in China.
- Anticipate numerous data readouts for various assets in different cancer types.
Challenges Ahead
- Potential delays in regulatory approvals.
- Uncertainties in clinical trial outcomes.
- Risks associated with commercializing new products.
- Dependence on partners for certain milestones.
- Impact of the COVID-19 pandemic on operations.